Skip to main content
Top

25-08-2016 | Systemic lupus erythematosus | Review | Article

The global burden of SLE: prevalence, health disparities and socioeconomic impact

Journal: Nature Reviews Rheumatology

Authors: Erin E. Carter, Susan G. Barr, Ann E. Clarke

Authors: Erin E. Carter, Susan G. Barr, Ann E. Clarke

Publisher: Nature Publishing Group UK

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can potentially lead to serious organ complications and even death. Its global burden — in terms of incidence and prevalence, differential impact on populations, economic costs and capacity to compromise health-related quality of life — remains incompletely understood. The reported worldwide incidence and prevalence of SLE vary considerably; this variation is probably attributable to a variety of factors, including ethnic and geographic differences in the populations being studied, the definition of SLE applied, and the methods of case identification. Despite the heterogeneous nature of the disease, distinct patterns of disease presentation, severity and course can often be related to differences in ethnicity, income level, education, health insurance status, level of social support and medication compliance, as well as environmental and occupational factors. Given the potential for the disease to cause such severe and widespread organ damage, not only are the attendant direct costs high, but these costs are sometimes exceeded by indirect costs owing to loss of economic productivity. As an intangible cost, patients with SLE are, not surprisingly, likely to endure considerably reduced health-related quality of life.

Nat Rev Rheumatol 2016;12:605–620. doi:10.1038/nrrheum.2016.137

Literature
1.
Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).CrossRefPubMed
2.
de Jesus, G. R. et al. Understanding and managing pregnancy in patients with lupus. Autoimmune Dis. 2015, http://​dx.​doi.​org/​10.​1155/​2015/​943490 (2015).
3.
Bernatsky, S. et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J. Autoimmun. 42, 130–135 (2013).CrossRefPubMedPubMedCentral
4.
Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 145, 408–415 (1997).CrossRefPubMed
5.
Aytan, J. & Bukhari, M. A. Use of biologics in SLE: a review of the evidence from a clinical perspective. Rheumatology (Oxford) 55, 775–779 (2016).CrossRef
6.
Uramoto, K. M. et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum. 42, 46–50 (1999).CrossRefPubMed
7.
Borchers, A. T., Naguwa, S. M., Shoenfeld, Y. & Gershwin, M. E. The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 9, A277–A287 (2010).CrossRefPubMed
8.
Laustrup, H., Voss, A., Green, A. & Junker, P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand. J. Rheumatol. 38, 128–132 (2009).CrossRefPubMed
9.
Lerang, K., Gilboe, I., Garen, T., Thelle, D. S. & Gran, J. T. High incidence and prevalence of systemic lupus erythematosus in Norway. Lupus 21, 1362–1369 (2012).CrossRefPubMed
10.
Nossent, H. C. Systemic lupus erythematosus in the Arctic region of Norway. J. Rheumatol. 28, 539–546 (2001).PubMed
11.
Alamanos, Y. et al. Epidemiology of systemic lupus erythematosus in northwest Greece 1982–2001. J. Rheumatol. 30, 731–735 (2003).PubMed
12.
Hopkinson, N. D., Doherty, M. & Powell, R. J. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989–1990. Br. J. Rheumatol. 32, 110–115 (1993).CrossRefPubMed
13.
Nightingale, A. L., Farmer, R. D. & de Vries, C. S. Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK general practice research database. Pharmacoepidemiol. Drug Saf. 15, 656–661 (2006).CrossRefPubMed
14.
Rees, F. et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann. Rheum. Dis. 75, 136–141 (2016).CrossRefPubMed
15.
Nasonov, E. et al. The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus 23, 213–219 (2014).CrossRefPubMed
16.
Malaviya, A. N., Singh, R. R., Singh, Y. N., Kapoor, S. K. & Kumar, A. Prevalence of systemic lupus erythematosus in India. Lupus 2, 115–118 (1993).CrossRefPubMed
17.
Chiu, Y. M. & Lai, C. H. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus 19, 1250–1255 (2010).CrossRefPubMed
18.
Yeh, K. W., Yu, C. H., Chan, P. C., Horng, J. T. & Huang, J. L. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol. Int. 33, 1805–1811 (2013).CrossRefPubMed
19.
Yu, K. H., See, L. C., Kuo, C. F., Chou, I. J. & Chou, M. J. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res. (Hoboken) 65, 244–250 (2013).CrossRef
20.
See, L. C., Kuo, C. F., Chou, I. J., Chiou, M. J. & Yu, K. H. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin. Arthritis Rheum. 43, 381–386 (2013).CrossRefPubMed
21.
Arnaud, L. et al. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun. Rev. 13, 1082–1089 (2014).CrossRefPubMed
22.
Shim, J. S., Sung, Y. K., Joo, Y. B., Lee, H. S. & Bae, S. C. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol. Int. 34, 909–917 (2014).CrossRefPubMed
23.
Ju, J. H. et al. Prevalence of systemic lupus erythematosus in South Korea: an administrative database study. J. Epidemiol. 24, 295–303 (2014).CrossRefPubMedPubMedCentral
24.
Somers, E. C. et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Rheumatol. 66, 369–378 (2014).CrossRefPubMedPubMedCentral
25.
Lim, S. S. et al. The incidence and prevalence of systemic lupus erythematosus, 2002–2004: the Georgia Lupus Registry. Arthritis Rheumatol. 66, 357–368 (2014).CrossRefPubMedPubMedCentral
26.
Gourley, I. S., Patterson, C. C. & Bell, A. L. The prevalence of systemic lupus erythematosus in Northern Ireland. Lupus 6, 399–403 (1997).CrossRefPubMed
27.
Farooqi, A. & Gibson, T. Prevalence of the major rheumatic disorders in the adult population of north Pakistan. Br. J. Rheumatol. 37, 491–495 (1998).CrossRefPubMed
28.
Moghimi, N. et al. WHO-ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. Clin. Rheumatol. 34, 535–543 (2015).CrossRefPubMed
29.
Sandoughi, M. et al. Prevalence of musculoskeletal disorders in southeastern Iran: a WHO-ILAR COPCORD study (stage 1, urban study). Int. J. Rheum. Dis. 16, 509–517 (2013).CrossRefPubMed
30.
Davatchi, F. et al. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin. Rheumatol. 28, 1275–1282 (2009).CrossRefPubMed
31.
Senna, E. R. et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J. Rheumatol. 31, 594–597 (2004).PubMed
32.
Granados, Y. et al. Prevalence of musculoskeletal disorders and rheumatic diseases in an urban community in Monagas State, Venezuela: a COPCORD study. Clin. Rheumatol. 34, 871–877 (2015).CrossRefPubMed
33.
Pelaez-Ballestas, I. et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J. Rheumatol. Suppl. 86, 3–8 (2011).CrossRefPubMed
34.
Reyes-Llerena, G. A. et al. Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J. Clin. Rheumatol. 15, 51–55 (2009).CrossRefPubMed
35.
Wang, F., Wang, C. L., Tan, C. T. & Manivasagar, M. Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus 6, 248–253 (1997).CrossRefPubMed
36.
Al-Rawi, Z., Al-Shaarbaf, H., Al-Raheem, E. & Khalifa, S. J. Clinical features of early cases of systemic lupus erythematosus in Iraqui patients. Br. J. Rheumatol. 22, 165–171 (1983).CrossRefPubMed
37.
Bossingham, D. Systemic lupus erythematosus in the far north of Queensland. Lupus 12, 327–331 (2003).CrossRefPubMed
38.
Shand, A. W., Algert, C. S., March, L. & Roberts, C. L. Second pregnancy outcomes for women with systemic lupus erythematosus. Ann. Rheum. Dis. 72, 547–551 (2013).CrossRefPubMed
39.
Segasothy, M. & Phillips, P. A. Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: A comparative study. Lupus 10, 439–444 (2001).CrossRefPubMed
40.
Molokhia, M., McKeigue, P. M., Cuadrado, M. & Hughes, G. Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK. Lancet 357, 1414–1415 (2001).CrossRefPubMed
41.
Alonso, M. D. et al. Systemic lupus erythematosus in northwestern Spain: a 20-year epidemiologic study. Medicine (Baltimore) 90, 350–358 (2011).CrossRef
42.
Lopez, P., Mozo, L., Gutierrez, C. & Suarez, A. Epidemiology of systemic lupus erythematosus in a northern spanish population: gender and age influence on immunological features. Lupus 12, 860–865 (2003).CrossRefPubMed
43.
Govoni, M., Castellino, G., Bosi, S., Napoli, N. & Trotta, F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. Lupus 15, 110–113 (2006).CrossRefPubMed
44.
Nived, O., Sturfelt, G. & Wollheim, F. Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br. J. Rheumatol. 24, 147–154 (1985).CrossRefPubMed
45.
Fessel, W. J. Systemic lupus erythematosus in the community. incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch. Intern. Med. 134, 1027–1035 (1974).CrossRefPubMed
46.
Hochberg, M. C. et al. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 4, 454–456 (1995).CrossRefPubMed
47.
Phan, J. C., Bush, T. M., Donald, F. & Ward, M. Clinical and laboratory features of patients of Vietnamese descent with systemic lupus erythematosus. Lupus 8, 521–524 (1999).CrossRefPubMed
48.
Barnabe, C. et al. Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada. Arthritis Care Res. (Hoboken) 64, 138–143 (2012).CrossRef
49.
Bernatsky, S. et al. A population-based assessment of systemic lupus erythematosus incidence and prevalence — results and implications of using administrative data for epidemiological studies. Rheumatology (Oxford) 46, 1814–1818 (2007).CrossRef
50.
Gudmundsson, S. & Steinsson, K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J. Rheumatol. 17, 1162–1167 (1990).PubMed
51.
Nossent, J. C. Systemic lupus erythematosus on the Caribbean island of Curaçao: an epidemiological investigation. Ann. Rheum. Dis. 51, 1197–1201 (1992).CrossRefPubMedPubMedCentral
52.
Zou, Y. F. et al. Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui province. Rheumatol. Int. 34, 347–356 (2014).CrossRefPubMed
53.
Cakir, N. et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol. Int. 32, 895–908 (2012).CrossRefPubMed
54.
Anagnostopoulos, I. et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet. Disord. 11, http://​dx.​doi.​org/​10.​1186/​1471-2474-11-98 (2010).
55.
Mok, C. C., To, C. H., Ho, L. Y. & Yu, K. L. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000–2006. J. Rheumatol. 35, 1978–1982 (2008).PubMed
56.
Iseki, K. et al. An epidemiologic analysis of end-stage lupus nephritis. Am. J. Kidney Dis. 23, 547–554 (1994).CrossRefPubMed
57.
Stahl-Hallengren, C., Jonsen, A., Nived, O. & Sturfelt, G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 27, 685–691 (2000).PubMed
58.
Ferucci, E. D. et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007–2009. Arthritis Rheumatol. 66, 2494–2502 (2014).CrossRefPubMedPubMedCentral
59.
Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with medicaid coverage, 2000–2004. Arthritis Rheum. 65, 753–763 (2013).CrossRefPubMedPubMedCentral
60.
Scolnik, M. et al. Incidence and prevalence of lupus in Buenos Aires, Argentina: an 11-year health management organisation-based study. Lupus Sci. Med. 1, http://​dx.​doi.​org/​10.​1136/​lupus-2014-000021 (2014).
61.
Naleway, A. L., Davis, M. E., Greenlee, R. T., Wilson, D. A. & McCarty, D. J. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 14, 862–866 (2005).CrossRefPubMed
62.
Sardu, C. et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS ONE 7, http://​dx.​doi.​org/​10.​1371/​journal.​pone.​0032487 (2012).
63.
Balluz, L. et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am. J. Epidemiol. 154, 1029–1036 (2001).CrossRefPubMed
64.
Vilar, M. J. & Sato, E. I. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 11, 528–532 (2002).CrossRefPubMed
65.
Garris, C., Shah, M. & Farrelly, E. The prevalence and burden of systemic lupus erythematosus in a Medicare population: retrospective analysis of Medicare claims. Cost Eff. Resour. Alloc. 13, http://​dx.​doi.​org/​10.​1186/​s12962-015-0034-z (2015).
66.
McMurray, R. W. & May, W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 48, 2100–2110 (2003).CrossRefPubMed
67.
Patel, M., Clarke, A. M., Bruce, I. N. & Symmons, D. P. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 54, 2963–2969 (2006).CrossRefPubMed
68.
Molokhia, M. & McKeigue, P. Systemic lupus erythematosus: genes versus environment in high risk populations. Lupus 15, 827–832 (2006).CrossRefPubMed
69.
Molokhia, M. & McKeigue, P. Risk for rheumatic disease in relation to ethnicity and admixture. Arthritis Res. 2, 115–125 (2000).CrossRefPubMedPubMedCentral
70.
Pons-Estel, G. J., Alarcon, G. S., Scofield, L., Reinlib, L. & Cooper, G. S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39, 257–268 (2010).CrossRefPubMed
71.
Vincent, F. B., Bourke, P., Morand, E. F., Mackay, F. & Bossingham, D. Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases. Intern. Med. J. 43, 227–234 (2013).CrossRefPubMed
72.
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 44, 2797–2806 (2001).CrossRefPubMed
73.
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups: II. features predictive of disease activity early in its course. LUMINA study group (lupus in minority populations, nature versus nurture). Arthritis Rheum. 41, 1173–1180 (1998).CrossRefPubMed
74.
Anderson, E., Nietert, P. J., Kamen, D. L. & Gilkeson, G. S. Ethnic disparities among patients with systemic lupus erythematosus in South Carolina. J. Rheumatol. 35, 819–825 (2008).PubMedPubMedCentral
75.
Gonzalez, L. A., Toloza, S. M., McGwin, G., Jr. & Alarcon, G. S. Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus 22, 1214–1224 (2013).CrossRefPubMed
76.
Ong, C., Nicholls, K. & Becker, G. Ethnicity and lupus nephritis: an Australian single centre study. Intern. Med. J. 41, 270–278 (2011).CrossRefPubMed
77.
Adelowo, O. O. & Oguntona, S. A. Pattern of systemic lupus erythematosus among Nigerians. Clin. Rheumatol. 28, 699–703 (2009).CrossRefPubMed
78.
Atisha-Fregoso, Y., Jakez-Ocampo, J. & Llorente, L. Systemic lupus erythematosus in Hispanics. Autoimmunity. 44, 555–561 (2011).CrossRefPubMed
79.
Pons-Estel, B. A. et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 83, 1–17 (2004).CrossRef
80.
Mok, M. Y. & Li, W. L. Do Asian patients have worse lupus? Lupus 19, 1384–1390 (2010).CrossRefPubMed
81.
Kaslow, R. A. High rate of death caused by systemic lupus erythematosus among U. S. residents of Asian descent. Arthritis Rheum. 25, 414–418 (1982).CrossRefPubMed
82.
Samanta, A. et al. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann. Rheum. Dis. 50, 490–492 (1991).CrossRefPubMedPubMedCentral
83.
Nossent, J. C. Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients. Semin. Arthritis Rheum. 23, 16–21 (1993).CrossRefPubMed
84.
Bernatsky, S. et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550–2557 (2006).CrossRefPubMed
85.
Krishnan, E. & Hubert, H. B. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann. Rheum. Dis. 65, 1500–1505 (2006).CrossRefPubMedPubMedCentral
86.
Wadee, S., Tikly, M. & Hopley, M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 46, 1487–1491 (2007).CrossRef
87.
Lau, C. S., Yin, G. & Mok, M. Y. Ethnic and geographical differences in systemic lupus erythematosus: An overview. Lupus 15, 715–719 (2006).CrossRefPubMed
88.
Gonzalez, L. A., Toloza, S. M. & Alarcon, G. S. Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 40, 433–454, (2014).CrossRefPubMed
89.
Petri, M., Perez-Gutthann, S., Longenecker, J. C. & Hochberg, M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am. J. Med. 91, 345–353 (1991).CrossRefPubMed
90.
Ward, M. M. & Studenski, S. Clinical manifestations of systemic lupus erythematosus. identification of racial and socioeconomic influences. Arch. Intern. Med. 150, 849–853 (1990).CrossRefPubMed
91.
Korbet, S. M., Schwartz, M. M., Evans, J. Lewis, E. J. & Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J. Am. Soc. Nephrol. 18, 244–254 (2007).CrossRefPubMed
92.
Nee, R. et al. Survival disparity of African American versus non-African American patients with ESRD due to SLE. Am. J. Kidney Dis. 66, 630–637 (2015).CrossRefPubMed
93.
Burgos, P. I. et al. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann. Rheum. Dis. 70, 393–394 (2011).CrossRefPubMed
94.
Thumboo, J. et al. A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1980 to 1992. Arthritis Rheum. 45, 494–500 (2001).CrossRefPubMed
95.
Gomez-Puerta, J. A. et al. Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. (Hoboken) 67, 1453–1462 (2015).CrossRef
96.
Heller, T., Ahmed, M., Siddiqqi, A., Wallrauch, C. & Bahlas, S. Systemic lupus erythematosus in Saudi Arabia: morbidity and mortality in a multiethnic population. Lupus 16, 908–914 (2007).CrossRefPubMed
97.
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in Minority Populations: Nature versus Nurture. Lupus 8, 197–209 (1999).CrossRefPubMed
98.
Cooper, G. S. et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11, 161–167 (2002).CrossRefPubMed
99.
Alarcon, G. S. et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann. Rheum. Dis. 65, 1168–1174 (2006).CrossRefPubMedPubMedCentral
100.
Malaviya, A. N., Chandrasekaran, A. N., Kumar, A. & Shamar, P. N. Systemic lupus erythematosus in India. Lupus 6, 690–700 (1997).CrossRefPubMed
101.
Connelly, K., Morand, E. F. & Hoi, A. Y. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Intern. Med. J. 43, 618–624 (2013).CrossRefPubMed
102.
Johnson, S. R., Urowitz, M. B., Ibanez, D. & Gladman, D. D. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J. Rheumatol. 33, 1990–1995 (2006).PubMed
103.
Reveille, J. D. et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA study group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Rheum. 41, 1161–1172 (1998).CrossRefPubMed
104.
Vina, E. R., Masi, C. M., Green, S. L. & Utset, T. O. A study of racial/ethnic differences in treatment preferences among lupus patients. Rheumatology (Oxford) 51, 1697–1706 (2012).CrossRef
105.
Karlson, E. W. et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum. 40, 47–56 (1997).CrossRefPubMed
106.
Odutola, J. & Ward, M. M. Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Curr. Opin. Rheumatol. 17, 147–152 (2005).CrossRefPubMed
107.
Al Dhanhani, A. M., Gignac, M. A., Su, J. & Fortin, P. R. Work disability in systemic lupus erythematosus. Arthritis Rheum. 61, 378–385 (2009).CrossRefPubMed
108.
Baker, K. & Pope, J. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology (Oxford) 48, 281–284 (2009).CrossRef
109.
Baker, K. et al. Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 18, 1281–1288 (2009).CrossRefPubMed
110.
Bertoli, A. M., Fernandez, M., Alarcon, G. S., Vila, L. M. & Reveille, J. D. Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability. Ann. Rheum. Dis. 66, 12–17 (2007).CrossRefPubMed
111.
Campbell, R., Jr., Cooper, G. S. & Gilkeson, G. S. The impact of systemic lupus erythematosus on employment. J. Rheumatol. 36, 2470–2475 (2009).CrossRefPubMed
112.
Drenkard, C. et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res. (Hoboken) 66, 878–887 (2014).CrossRef
113.
Lau, C. S. & Mak, A. The socioeconomic burden of SLE. Nat. Rev. Rheumatol. 5, 400–404 (2009).CrossRefPubMed
114.
Walsh, S. J. & Gilchrist, A. Geographical clustering of mortality from systemic lupus erythematosus in the United States: contributions of poverty, Hispanic ethnicity and solar radiation. Lupus 15, 662–670 (2006).CrossRefPubMed
115.
Richiardi, L., Bellocco, R. & Zugna, D. Mediation analysis in epidemiology: methods, interpretation and bias. Int. J. Epidemiol. 42, 1511–1519 (2013).CrossRefPubMed
116.
Alarcon, G. S. Lessons from LUMINA: a multiethnic US cohort. Lupus 17, 971–976 (2008).CrossRefPubMed
117.
Alarcon, G. S. et al. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. Arthritis Rheum. 51, 73–77 (2004).CrossRefPubMed
118.
Kasitanon, N., Magder, L. S. & Petri, M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 85, 147–156 (2006).CrossRef
119.
Fangtham, M. & Petri, M. 2013 Update: Hopkins lupus cohort. Curr. Rheumatol. Rep. 15 http://​dx.​doi.​org/​10.​1007/​s11926-013-0360-0 (2013).
120.
Burling, F. et al. Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort. Lupus 16, 830–837 (2007).CrossRefPubMed
121.
Barr, R. G. et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol. Dial. Transplant. 18, 2039–2046 (2003).CrossRefPubMed
122.
Ward, M. M. Education level and mortality in systemic lupus erythematosus (SLE): evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels. Arthritis Rheum. 51, 616–624 (2004).CrossRefPubMed
123.
Escalante, A. & del Rincon, I. Epidemiology and impact of rheumatic disorders in the United States Hispanic population. Curr. Opin. Rheumatol. 13, 104–110 (2001).CrossRefPubMed
124.
Kumar, K. et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and white British origin. Rheumatology (Oxford) 47, 690–697 (2008).CrossRef
125.
Costenbader, K. H. et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 50, 849–857 (2004).CrossRefPubMed
126.
Jiang, F., Li, S. & Jia, C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin. Rheumatol. 34, 1885–1892 (2015).CrossRefPubMed
127.
Hardy, C. J., Palmer, B. P., Muir, K. R., Sutton, A. J. & Powell, R. J. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case–control study. Ann. Rheum. Dis. 57, 451–455 (1998).CrossRefPubMedPubMedCentral
128.
Takvorian, S. U., Merola, J. F. & Costenbader, K. H. Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus. Lupus 23, 537–544 (2014).CrossRefPubMed
129.
Rubin, R. L. et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol. Sci. 87, 86–96 (2005).CrossRefPubMed
130.
Ghaussy, N. O., Sibbitt, W. Jr., Bankhurst, A. D. & Qualls, C. R. Cigarette smoking and disease activity in systemic lupus erythematosus. J. Rheumatol. 30, 1215–1221 (2003).PubMed
131.
Ward, M. M. & Studenski, S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch. Intern. Med. 152, 2082–2088 (1992).CrossRefPubMed
132.
Wang, J., Pan, H. F., Ye, D. Q., Su, H. & Li, X. P. Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis. Clin. Rheumatol. 27, 1557–1563 (2008).CrossRefPubMed
133.
Bengtsson, A. A., Rylander, L., Hagmar, L., Nived, O. & Sturfelt, G. Risk factors for developing systemic lupus erythematosus: a case–control study in southern Sweden. Rheumatology (Oxford) 41, 563–571 (2002).CrossRef
134.
Wang, J., Kay, A. B., Fletcher, J., Formica, M. K. & McAlindon, T. E. Alcohol consumption is not protective for systemic lupus erythematosus. Ann. Rheum. Dis. 68, 345–348 (2009).CrossRefPubMed
135.
Formica, M. K., Palmer, J. R., Rosenberg, L. & McAlindon, T. E. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health study. J. Rheumatol. 30, 1222–1226 (2003).PubMed
136.
Farhat, S. C. et al. Air pollution in autoimmune rheumatic diseases: a review. Autoimmun Rev. 11, 14–21 (2011).CrossRefPubMed
137.
Cooper, G. S. et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 49, 2172–2180 (2010).CrossRef
138.
Cooper, G. S., Miller, F. W. & Germolec, D. R. Occupational exposures and autoimmune diseases. Int. Immunopharmacol. 2, 303–313 (2002).CrossRefPubMed
139.
Parks, C. G. & Cooper, G. S. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 15, 728–736 (2006).CrossRefPubMed
140.
Parks, C. G. et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case–control study in the southeastern United States. Arthritis Rheum. 46, 1840–1850 (2002).CrossRefPubMed
141.
Conrad, K., Mehlhorn, J., Luthke, K., Dorner, T. & Frank, K. H. Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 5, 62–69 (1996).CrossRefPubMed
142.
Sanchez-Roman, J., Wichmann, I., Salaberri, J., Varela, J. M. & Nunez-Roldan, A. Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann. Rheum. Dis. 52, 534–538 (1993).CrossRefPubMedPubMedCentral
143.
Finckh, A. et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 54, 3648–3654 (2006).CrossRefPubMed
144.
Dahlgren, J. et al. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ. Health 6, http://​dx.​doi.​org/​10.​1186/​1476-069X-6-8 (2007).
145.
Bernatsky, S. et al. Associations between ambient fine particulate levels and disease activity in patients with systemic lupus erythematosus (SLE). Environ. Health Perspect. 119, 45–49 (2011).CrossRefPubMed
146.
Parks, C. G. & De Roos, A. J. Pesticides, chemical and industrial exposures in relation to systemic lupus erythematosus. Lupus 23, 527–536 (2014).CrossRefPubMedPubMedCentral
147.
Cooper, G. S. et al. Occupational risk factors for the development of systemic lupus erythematosus. J. Rheumatol. 31, 1928–1933 (2004).PubMed
148.
Kilburn, K. H. & Warshaw, R. H. Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ. Res. 57, 1–9 (1992).CrossRefPubMed
149.
Sahebari, M., Nabavi, N. & Salehi, M. Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders. Lupus 23, 1164–1177 (2014).CrossRefPubMed
150.
Breslin, L. C., Magee, P. J., Wallace, J. M. & McSorley, E. M. An evaluation of vitamin D status in individuals with systemic lupus erythematosus. Proc. Nutr. Soc. 70, 399–407 (2011).CrossRefPubMed
151.
de Souza, V. A. et al. Association of hypovitaminosis D with systemic lupus erythematosus and inflammation. J. Bras. Nefrol. 36, 430–436 (2014).PubMed
152.
Fragoso, T. S. et al. 25-hydroxyivitamin D3 levels in patients with systemic lupus erythematosus and its association with clinical parameters and laboratory tests. Rev. Bras. Reumatol. 52, 60–65 (2012).CrossRefPubMed
153.
Hamza, R. T., Awwad, K. S., Ali, M. K. & Hamed, A. I. Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity. Med. Sci. Monit. 17, CR711–CR718 (2011).CrossRefPubMedPubMedCentral
154.
Abe, J. et al. Prevention of immunological disorders in Mrl/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1α, 25-dihydroxyvitamin D3. J. Nutr. Sci. Vitaminol. (Tokyo) 36, 21–31 (1990).CrossRef
155.
Lemire, J. M., Ince, A. & Takashima, M. 1,25-dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of Mrl/l mice. Autoimmunity 12, 143–148 (1992).CrossRefPubMed
156.
Yap, K. et al. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci. Med. 2, http://​dx.​doi.​org/​10.​1136/​lupus-2014-000064 (2015).
157.
Mok, C. C. et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 21, 36–42 (2012).CrossRefPubMed
158.
McGhie, T. K., DeCeulaer, K., Walters, C. A., Soyibo, A. & Lee, M. G. Vitamin D levels in Jamaican patients with systemic lupus erythematosus. Lupus 23, 1092–1096 (2014).CrossRefPubMed
159.
Barbhaiya, M. & Costenbader, K. H. Ultraviolet radiation and systemic lupus erythematosus. Lupus 23, 588–595 (2014).CrossRefPubMed
160.
Schneider, L. et al. Vitamin D levels and cytokine profiles in patients with systemic lupus erythematosus. Lupus 24, 1191–1197 (2015).CrossRefPubMed
161.
Munoz-Ortego, J., Torrente-Segarra, V., Prieto-Alhambra, D., Salman-Monte, T. C. & Carbonell-Abello, J. Prevalence and predictors of vitamin D deficiency in non-supplemented women with systemic lupus erythematosus in the Mediterranean region: a cohort study. Scand. J. Rheumatol. 41, 472–475 (2012).CrossRefPubMed
162.
Schneider, L., Dos Santos, A. S., Santos, M., da Silva Chakr, R. M. & Monticielo, O. A. Vitamin D and systemic lupus erythematosus: state of the art. Clin. Rheumatol. 33, 1033–1038 (2014).PubMed
163.
Somers, E. C., Thomas, S. L., Smeeth, L., Schoonen, W. M. & Hall, A. J. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum. 57, 612–618 (2007).CrossRefPubMed
164.
Szeto, C. C. et al. Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong. J. Rheumatol. 35, 1031–1037 (2008).PubMed
165.
Duarte-Garcia, A., Fang, H., To, C. H., Magder, L. S. & Petri, M. Seasonal variation in the activity of systemic lupus erythematosus. J. Rheumatol. 39, 1392–1398 (2012).CrossRefPubMedPubMedCentral
166.
Panopalis, P. et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 59, 1788–1795 (2008).CrossRefPubMedPubMedCentral
167.
Huscher, D. et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65, 1175–1183 (2006).CrossRefPubMedPubMedCentral
168.
Jonsen, A. et al. Total cost and cost predictors in systemic lupus erythematosus — 8-years follow-up of a Swedish inception cohort. Lupus 24, 1248–1256 (2015).CrossRefPubMed
169.
Bexelius, C., Wachtmeister, K., Skare, P., Jonsson, L. & Vollenhoven, R. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 22, 793–801 (2013).CrossRefPubMed
170.
Doria, A. et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann. Rheum. Dis. 73, 154–160 (2014).CrossRefPubMed
171.
Sutcliffe, N., Clarke, A. E., Taylor, R., Frost, C. & Isenberg, D. A. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 40, 37–47 (2001).CrossRef
172.
Cho, J. et al. Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea. Lupus 23, 949–957 (2014).CrossRefPubMed
173.
Zhu, T. Y., Tam, L. S., Lee, V. W., Lee, K. K. & Li, E. K. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 48, 564–568 (2009).CrossRef
174.
Zhu, T. Y., Tam, L. S., Lee, V. W., Lee, K. K. & Li, E. K. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. 61, 1159–1167 (2009).CrossRefPubMed
175.
Li, T. et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum. 61, 755–763 (2009).CrossRefPubMed
176.
Garris, C. et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J. Med. Econ. 16, 667–677 (2013).CrossRefPubMed
177.
Kan, H. et al. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J. Med. Econ. 16, 793–800 (2013).CrossRefPubMed
178.
Kan, H. J. et al. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed. Res. Int. 2013, http://​dx.​doi.​org/​10.​1155/​2013/​808391 (2013).
179.
Narayanan, S., Wilson, K., Ogelsby, A., Juneau, P. & Durden, E. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J. Occup. Environ. Med. 55, 1262–1270 (2013).CrossRefPubMed
180.
Furst, D. E. et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. J. Med. Econ. 16, 500–509 (2013).CrossRefPubMed
181.
Furst, D. E. et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus 22, 268–278 (2013).CrossRefPubMed
182.
Oglesby, A. et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl. Health Econ. Health Policy 12, 179–190 (2014).CrossRefPubMed
183.
Pelletier, E. M., Ogale, S., Yu, E., Brunetta, P. & Garg, J. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin. Ther. 31, 2653–2664 (2009).CrossRefPubMed
184.
Carls, G. et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J. Occup. Environ. Med. 51, 66–79 (2009).CrossRefPubMed
185.
Clarke, A. E. et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 47, 329–333 (2008).CrossRef
186.
Clarke, A. E. et al. The systemic lupus erythematosus Tri-Nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 43, 1016–1024 (2004).CrossRef
187.
Clarke, A. E., Urowitz, M. B., Monga, N. & Hanly, J. G. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. Arthritis Care Res. (Hoboken) 67, 431–436 (2015).CrossRef
188.
Aghdassi, E. et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J. Rheumatol. 38, 658–666 (2011).CrossRefPubMed
189.
Gordon, C. et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford) 52, 2292–2301 (2013).CrossRef
190.
Panopalis, P. et al. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum. 57, 64–70 (2007).CrossRefPubMed
191.
Scofield, L., Reinlib, L., Alarcon, G. S. & Cooper, G. S. Employment and disability issues in systemic lupus erythematosus: a review. Arthritis Rheum. 59, 1475–1479 (2008).CrossRefPubMed
192.
Mok, C. C., Cheung, M. Y., Ho, L. Y., Yu, K. L. & To, C. H. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Lupus 17, 1103–1107 (2008).CrossRefPubMed
193.
Yelin, E. et al. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample. Arthritis Rheum. 61, 247–258 (2009).CrossRefPubMedPubMedCentral
194.
Zhu, T. Y., Tam, L. S. & Li, E. K. Labour and non-labour market productivity in Chinese patients with systemic lupus erythematosus. Rheumatology (Oxford) 51, 284–292 (2012).CrossRef
195.
Yelin, E. et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum. 57, 56–63 (2007).CrossRefPubMedPubMedCentral
196.
Schmeding, A. & Schneider, M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 27, 363–375 (2013).CrossRefPubMed
197.
Mau, W., Listing, J., Huscher, D., Zeidler, H. & Zink, A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J. Rheumatol. 32, 721–728 (2005).PubMed
198.
Utset, T. O. et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci. Med. 2, http://​dx.​doi.​org/​10.​1136/​lupus-2014-000058 (2015).
199.
Jetha, A. et al. Unpacking early work experiences of young adults with rheumatic disease: an examination of absenteeism, job disruptions and productivity loss. Arthritis Care Res. (Hoboken) 67, 1246–1254 (2015).CrossRef
200.
Garris, C., Oglesby, A., Sulcs, E. & Lee, M. Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States. Lupus 22, 1077–1086 (2013).CrossRefPubMed
201.
Al Dhanhani, A. M., Gignac, M. A., Beaton, D. E., Su, J. & Fortin, P. R. Work factors are associated with workplace activity limitations in systemic lupus erythematosus. Rheumatology (Oxford) 53, 2044–2052 (2014).CrossRef
202.
Dua, A. B., Touma, Z., Toloza, S. & Jolly, M. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr. Rheumatol. Rep. 15, http://​dx.​doi.​org/​10.​1007/​s11926-013-0380-9 (2013).
203.
Mosca, M. et al. European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann. Rheum. Dis. 69, 1269–1274 (2010).CrossRefPubMed